New Framework Sheds Light on Behçet's Spectrum Disorders in Children

For children with unexplained fevers, painful mouth sores, and gut inflammation that look like Behçet's disease (BD) but don't quite fit the diagnosis, doctors have long faced a clinical puzzle. Now, researchers have formalized a concept that may help solve it: Behçet's spectrum disorders (BSD). First introduced in 2020, the BSD framework pulls together a diverse set of inflammatory conditions, from rare monogenic diseases to common recurrent canker sores, united by shared immune pathways. This approach helps clinicians recognize Behçet-like inflammation earlier and prioritize genetic testing in children whose symptoms fall outside classic diagnostic patterns.

Behçet's disease (BD) is a systemic vasculitis marked by recurrent oral and genital ulcers, but paediatric presentations are often partial or atypical, complicating diagnosis. Moreover, a growing number of monogenic autoinflammatory disorders produce nearly identical mucocutaneous and gastrointestinal symptoms, yet they are biologically distinct and require different therapeutic approaches. This diagnostic overlap frequently leads to misdiagnosis, inappropriate treatment, and prolonged suffering. Although the "Behçet's spectrum disorders" (BSD) concept was introduced in 2020 to link these conditions through shared inflammatory pathways, a practical, clinically applicable framework for early recognition and genetic prioritisation in children has remained elusive. Based on these challenges, there is a pressing need to conduct in‑depth research that systematises these disorders and translates mechanistic knowledge into actionable clinical strategies.

Now, a team from Peking Union Medical College Hospital in Beijing has published (DOI: 10.1007/s12519-026-01035-4) a review article in the World Journal of Pediatrics published June 23, 2026) that comprehensively maps out the Behçet's spectrum disorders. The researchers propose a tiered classification: "core Behçet's spectrum disorders (BSD)" for monogenic diseases that directly converge on Behçet's-defining inflammatory pathways, and "peripheral BSD" for conditions with partial clinical overlap or indirect mechanistic connections. The goal is not to replace existing diagnostic criteria but to provide a mechanism-oriented lens for earlier recognition and genetic screening in children with Behçet-like presentations.

This systematic review establishes a two‑tier BSD classification grounded in genetic and mechanistic evidence. The core BSD tier comprises monogenic diseases that directly disrupt NF‑κB or JAK‑STAT signalling—specifically HA20 (caused by TNFAIP3 mutations), RELA haploinsufficiency, NFKB1 haploinsufficiency, and ELF4 deficiency. These conditions consistently feature recurrent mucocutaneous ulceration and show strong convergence on BD‑relevant inflammatory circuits. The peripheral BSD tier includes polygenic or multifactorial entities such as recurrent aphthous stomatitis (RAS), PFAPA syndrome, DADA2, and trisomy 8‑associated disease, which exhibit partial clinical overlap or indirect pathway engagement but lack a defining monogenic driver. A major highlight is the identification of NF‑κB and JAK‑STAT as two central inflammatory hubs that serve as common denominators across the entire spectrum, providing a rational basis for grouping these diverse disorders. The authors also carefully delineate exclusion criteria, distinguishing true spectrum members from phenotypic mimics like LIG4 deficiency and IKBKG (NEMO) mutations, thereby sharpening diagnostic boundaries. Importantly, the framework does not replace existing BD criteria but offers a mechanism‑oriented lens to prioritise genetic testing in early‑onset or atypical paediatric cases, significantly reducing diagnostic odysseys. This tiered, biology‑driven approach marks a paradigm shift from purely symptom‑based classification to stratified, mechanism‑informed nosology.

Clinically, the BSD framework enables earlier recognition of Behçet‑like phenotypes and guides rational genetic testing, allowing targeted therapies—such as IL‑1, TNF, or JAK inhibitors—for specific subsets. It also helps exclude non‑spectrum mimics, avoiding unnecessary investigations and expediting effective care. Scientifically, it unifies disparate inflammatory disorders under shared pathogenic axes, fostering collaborative research and paving the way for biomarker discovery and mechanism‑based trials. Ultimately, this framework empowers paediatricians to move beyond trial‑and‑error management towards precision medicine, offering tangible hope for children with complex, refractory inflammatory conditions that have long defied conventional diagnosis and treatment.

"We're not saying these are all the same disease—they're not," the authors said. "But they converge on the same inflammatory circuits. If a child shows up with recurrent mouth ulcers, fever, and gut inflammation that doesn't quite fit Behçet's criteria, the BSD framework gives us a roadmap for what to test for and why." They emphasized that the framework is especially valuable in early-onset or atypical cases, where genetic testing can distinguish between conditions that look alike but respond to very different treatments.